Neoadjuvant camrelizumab plus chemotherapy in treating locally advanced esophageal squamous cell carcinoma patients: a pilot study

[11] Hung WH(2020)The safety and efficacy of apatinib treatment in addition to concurrent chemoradiotherapy in patients with nonoperative locally advanced esophageal squamous cell carcinoma Med Sci Monit. 26 e927221-1357

[12] Lin CH(2020)Feasibility study of nivolumab as neoadjuvant chemotherapy for locally esophageal carcinoma: FRONTiER (JCOG1804E) Future Oncol. 16 1351-742

[13] Zhu Z(2020)PD-1/PD-L1 pathway: current researches in cancer Am J Cancer Res. 10 727-1268

[14] Wang Y(2020)Immune checkpoint inhibitor-related dermatologic adverse events J Am Acad Dermatol. 83 1255-720

[15] Li F(2020)Protocol for a randomized controlled trial of perioperative S-1 plus oxaliplatin combined with apatinib and camrelizumab in patients with resectable, locally advanced gastric or gastroesophageal junction adenocarcinoma Ann Transl Med. 8 1684-e1e24

[16] Gao J(2021)Improved clinical outcome in a randomized phase II study of anti-PD-1 camrelizumab plus decitabine in relapsed/refractory Hodgkin lymphoma J Immunother Cancer. 9 e002347-1126

[17] Han B(2020)Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first-line treatment of advanced esophageal squamous cell carcinoma Cancer Commun 40 711-137

[18] Wang R(2021)Safety and feasibility of radiotherapy plus camrelizumab for locally advanced esophageal squamous cell carcinoma Oncologist. 26 e1110-2686

[19] Pasquali S(2017)Interpretation of 2017 National Comprehensive Cancer Network (NCCN) guidelines for the diagnosis and treatment of esophageal squamous cell carcinoma through the new TNM staging of esophageal carcinoma (eighth edition) by the Union for International Cancer Control (UICC) and the American Cancer Commission (AJCC) Zhonghua Wei Chang Wai Ke Za Zhi. 20 1122-1355

[20] Yim G(2016)RECIST 1.1-Update and clarification: from the RECIST committee Eur J Cancer. 62 132-216

[11] Hung WH(2020)The safety and efficacy of apatinib treatment in addition to concurrent chemoradiotherapy in patients with nonoperative locally advanced esophageal squamous cell carcinoma Med Sci Monit. 26 e927221-1357

[12] Lin CH(2020)Feasibility study of nivolumab as neoadjuvant chemotherapy for locally esophageal carcinoma: FRONTiER (JCOG1804E) Future Oncol. 16 1351-742

[13] Zhu Z(2020)PD-1/PD-L1 pathway: current researches in cancer Am J Cancer Res. 10 727-1268

[14] Wang Y(2020)Immune checkpoint inhibitor-related dermatologic adverse events J Am Acad Dermatol. 83 1255-720

[15] Li F(2020)Protocol for a randomized controlled trial of perioperative S-1 plus oxaliplatin combined with apatinib and camrelizumab in patients with resectable, locally advanced gastric or gastroesophageal junction adenocarcinoma Ann Transl Med. 8 1684-e1e24

[16] Gao J(2021)Improved clinical outcome in a randomized phase II study of anti-PD-1 camrelizumab plus decitabine in relapsed/refractory Hodgkin lymphoma J Immunother Cancer. 9 e002347-1126

[17] Han B(2020)Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first-line treatment of advanced esophageal squamous cell carcinoma Cancer Commun 40 711-137

[18] Wang R(2021)Safety and feasibility of radiotherapy plus camrelizumab for locally advanced esophageal squamous cell carcinoma Oncologist. 26 e1110-2686

[19] Pasquali S(2017)Interpretation of 2017 National Comprehensive Cancer Network (NCCN) guidelines for the diagnosis and treatment of esophageal squamous cell carcinoma through the new TNM staging of esophageal carcinoma (eighth edition) by the Union for International Cancer Control (UICC) and the American Cancer Commission (AJCC) Zhonghua Wei Chang Wai Ke Za Zhi. 20 1122-1355

[20] Yim G(2016)RECIST 1.1-Update and clarification: from the RECIST committee Eur J Cancer. 62 132-216